154 related articles for article (PubMed ID: 15151636)
1. Regression of a hepatocellular carcinoma following treatment with octreotide and tamoxifen in a patient with advanced alcoholic cirrhosis.
Senturk H; Canbakan B; Cumali R
J Gastroenterol Hepatol; 2004 Jun; 19(6):719-20. PubMed ID: 15151636
[No Abstract] [Full Text] [Related]
2. A dramatic response to long-acting octreotide in metastatic hepatocellular carcinoma.
Deming DA; Stella AL; Holen KD; Ku G; O'Reilly EM
Clin Adv Hematol Oncol; 2005 Jun; 3(6):468-72; discussion 472-4. PubMed ID: 16167024
[No Abstract] [Full Text] [Related]
3. [Tamoxifen and hepatocarcinoma].
Mondragón Sánchez R
Rev Gastroenterol Mex; 1998; 63(3):169. PubMed ID: 10068765
[No Abstract] [Full Text] [Related]
4. Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial.
Pan DY; Qiao JG; Chen JW; Huo YC; Zhou YK; Shi HA
Hepatobiliary Pancreat Dis Int; 2003 May; 2(2):211-5. PubMed ID: 14599971
[TBL] [Abstract][Full Text] [Related]
5. Complete regression of hepatocellular carcinoma under tamoxifen.
Castéra L; Boige V; Rocher L; Duclos-Vallée JC; Fabre M; Buffet C
Am J Gastroenterol; 2000 Mar; 95(3):827-9. PubMed ID: 10710095
[No Abstract] [Full Text] [Related]
6. Complete, long-standing regression of hepatocellular carcinoma after somatostatin analogue treatment.
Rahmi G; Malka D; Tomasic G; Dromain C; Ducreux M; Boige V
J Clin Oncol; 2007 Jun; 25(16):e15-6. PubMed ID: 17538153
[No Abstract] [Full Text] [Related]
7. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study.
Verset G; Verslype C; Reynaert H; Borbath I; Langlet P; Vandebroek A; Peeters M; Houbiers G; Francque S; Arvanitakis M; Van Laethem JL
Br J Cancer; 2007 Sep; 97(5):582-8. PubMed ID: 17687341
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.
Lu YS; Hsu C; Li CC; Kuo SH; Yeh KH; Yang CH; Hsu CH; Wu CY; Cheng AL
Hepatogastroenterology; 2004; 51(57):815-9. PubMed ID: 15143923
[TBL] [Abstract][Full Text] [Related]
9. Multimodal therapy for liver cirrhosis patients with advanced hepatocellular carcinoma.
Nagai H; Matsui T; Kanayama M; Wakui N; Momiyama K; Watanabe M; Igarashi Y; Sumino Y
Cancer Chemother Pharmacol; 2011 Jul; 68(1):139-45. PubMed ID: 20857114
[TBL] [Abstract][Full Text] [Related]
10. The role of sandostatin LAR in treating patients with advanced hepatocellular cancer.
Dimitroulopoulos D; Xinopoulos D; Tsamakidis K; Zisimopoulos A; Andriotis E; Markidou S; Panagiotakos D; Chrysohoou C; Bazinis A; Paraskevas E
Hepatogastroenterology; 2002; 49(47):1245-50. PubMed ID: 12239914
[TBL] [Abstract][Full Text] [Related]
11. The results of a randomized study on the use of long-acting octreotide in hepatocellular carcinoma.
Borbath I; Horsmans Y
Hepatology; 2003 Feb; 37(2):477-8; author reply 478. PubMed ID: 12575712
[No Abstract] [Full Text] [Related]
12. [Metastatic breast carcinoma with neuroendocrine differentiation--its combined therapy with tamoxifen and the somatostatin analog octreotide].
Rischke HC; Staib-Sebler E; Mose S; Adams SW; Herrmann G; Böttcher HD; Lorenz M
Dtsch Med Wochenschr; 1999 Feb; 124(7):182-6. PubMed ID: 10093577
[TBL] [Abstract][Full Text] [Related]
13. Systemic treatment of hepatocellular carcinoma.
Treiber G
Dig Dis; 2001; 19(4):311-23. PubMed ID: 11935091
[TBL] [Abstract][Full Text] [Related]
14. Education and Imaging. Hepatobiliary and Pancreatic: Complete remission after hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with decompensated cirrhosis.
Seo JH; Song MJ
J Gastroenterol Hepatol; 2016 Jan; 31(1):10. PubMed ID: 26177574
[No Abstract] [Full Text] [Related]
15. Complete remission of multiple hepatocellular carcinomas associated with hepatitis C virus-related, decompensated liver cirrhosis by oral administration of enteric-coated tegafur/uracil.
Ishikawa T; Ichida T; Ishimoto Y; Yokoyama J; Nomoto M; Ebe Y; Usuda H; Naito M; Asakura H
Am J Gastroenterol; 1999 Jun; 94(6):1682-5. PubMed ID: 10364045
[TBL] [Abstract][Full Text] [Related]
16. Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study.
Cappa FM; Cantarini MC; Magini G; Zambruni A; Bendini C; Santi V; Bernardi M; Trevisani F
Dig Liver Dis; 2005 Apr; 37(4):254-9. PubMed ID: 15788209
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma.
Riestra S; Rodriguez M; Delgado M; Suárez A; González N; de la Mata M; Diaz G; Miño-Fugarolas G; Rodrigo L
J Clin Gastroenterol; 1998 Apr; 26(3):200-3. PubMed ID: 9600369
[TBL] [Abstract][Full Text] [Related]
18. Acute hemoperitoneum from rupture of a hepatocellular carcinoma.
Clarkston W; Inciardi M; Kirkpatrick S; McEwen G; Ediger S; Schubert T
J Clin Gastroenterol; 1988 Apr; 10(2):221-5. PubMed ID: 2843591
[TBL] [Abstract][Full Text] [Related]
19. Spontaneous regression of hepatocellular carcinoma. A case report.
Clos A; Hernández A; Sánchez MD; Tenesa M; Julián JF; Armengol C; Sala M
Gastroenterol Hepatol; 2017 Apr; 40(4):286-288. PubMed ID: 26994525
[No Abstract] [Full Text] [Related]
20. [Cranial metastasis revealing hepatic carcinoma with cirrhosis. An exceptional case in a 56-year-old man].
Biwole Sida M; Andze G; Juimo AG; Nko'o Amvene ; Nouedoui C; Kingue S; Fouda F; Muna WT
Ann Gastroenterol Hepatol (Paris); 1993; 29(6):283-5. PubMed ID: 8117054
[No Abstract] [Full Text] [Related]
[Next] [New Search]
